Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer.

Biographies:
Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer Institute, Harvard Medical School

Alicia Morgans, MD, MPH

Related Content: 

Watch: Perspective on Molecular Characterization - Himisha Beltran